• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Affimed N.V. (Amendment)

    2/14/23 4:01:29 PM ET
    $AFMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AFMD alert in real time by email
    SC 13G/A 1 pt7213gaa.htm SCHEDULE 13G/A, AMENDMENT #2
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.

    Securities and Exchange Commission, Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

    (Name of Issuer)

    Affimed N.V.

    (Title of Class of Securities)

    Common Shares, nominal value €0.01 per share

    (CUSIP Number)

    N01045108 (a)

    (Date of Event Which Requires Filing of this Statement)

    December 31, 2022

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:

    [  ] Rule 13d-1(b)

    [ x ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).


    (a) The Common Shares have no CUSIP.   The CINS number for the Common Shares is N01045108.


    CUSIP No. N01045108
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              4,207,220
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       4,207,220
     
    (9) Aggregate amount beneficially owned by each reporting person
    4,207,220
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 2.8%
     
    (12) Type of reporting person (see instructions) PN
     



    CUSIP No. N01045108
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              4,207,220
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       4,207,220
     
    (9) Aggregate amount beneficially owned by each reporting person
    4,207,220
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 2.8%
     
    (12) Type of reporting person (see instructions) CO
     



    CUSIP No. N01045108
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              10,400
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       10,400
     
    (9) Aggregate amount beneficially owned by each reporting person
    10,400
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1%
     
    (12) Type of reporting person (see instructions) OO
     



    CUSIP No. N01045108
    (1) Names of reporting persons    Point72 Middle East FZE
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United Arab Emirates
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              9,393
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       9,393
     
    (9) Aggregate amount beneficially owned by each reporting person
    9,393
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1%
     
    (12) Type of reporting person (see instructions) OO
     



    CUSIP No. N01045108
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              4,227,013
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       4,227,013
     
    (9) Aggregate amount beneficially owned by each reporting person
    4,227,013
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 2.8%
     
    (12) Type of reporting person (see instructions) IN
     




    Item 1(a) Name of issuer:

    Affimed N.V.

    Item 1(b) Address of issuer's principal executive offices:

    Im Neuenheimer Feld 582, 69120 Heidelberg, Germany

    2(a) Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common shares, nominal value €0.01 per share
    (“Shares”), of the Issuer held by an investment fund it manages; (ii) Point72 Capital Advisors,
    Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by an investment fund
    managed by Point72 Asset Management; (iii) Cubist Systematic Strategies, LLC (“Cubist
    Systematic Strategies”) with respect to Shares held by an investment fund it manages; (iv)
    Point72 Middle East FZE (“Point72 Middle East”) with respect to Shares held by an investment
    fund it manages; and (v) Steven A. Cohen (“Mr. Cohen”) with respect to Shares beneficially
    owned by Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, and Point72 Middle East.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, Point72 Middle East, and Mr. Cohen have entered into a Joint Filing
    Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1,
    pursuant to which they have agreed to file this Schedule 13G jointly in
    accordance with the provisions of Rule 13d-1(k) of the Act.

    2(b) Address or principal business office or, if none, residence:

    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road,
    Stamford, CT 06902; (ii) Cubist Systematic Strategies is 55 Hudson Yards,
    New York, NY 10001; and (iii) Point72 Middle East is EO3, 04, Sheikh Rashid Tower,
    Dubai World Trade Centre, Dubai, United Arab Emirates.

    2(c) Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a
    Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company.
    Point72 Middle East is a limited liability free zone establishment. Mr. Cohen is a United States
    citizen.

    2(d) Title of class of securities:

    Common Shares, nominal value €0.01 per share

    2(e) CUSIP Number:

    N01045108

    Item 3.

    Not applicable


    Item 4. Ownership

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for
    each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
    Such information is as of the close of business on December 31, 2022.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, Point72 Middle East, and Mr. Cohen own directly no Shares. Pursuant
    to an investment management agreement, Point72 Asset Management maintains
    investment and voting power with respect to the securities held by an investment fund it
    manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management.
    Pursuant to an investment management agreement, Cubist Systematic Strategies maintains
    investment and voting power with respect to the securities held by an investment fund it
    manages. Pursuant to an investment management agreement, Point72 Middle East maintains
    investment and voting power with respect to the securities held by an investment fund it
    manages. Mr. Cohen controls each of Point72 Asset Management, Point72 Capital Advisors Inc.,
    Cubist Systematic Strategies, and Point72 Middle East.   The filing of this statement should not
    be construed as an admission that any of the foregoing persons or any reporting person is, for the
    purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

    Item 5.  Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [X].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    See Item 2(a).

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.

    Not applicable

    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to
    above were not acquired and are not held for the purpose of or with the effect of changing or
    influencing the control of the issuer of the securities and were not acquired and are not held in
    connection with or as a participant in any transaction having that purpose or effect.


    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.


    Dated: February 14, 2023


    POINT72 ASSET MANAGEMENT, L.P.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 CAPITAL ADVISORS, INC.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    CUBIST SYSTEMATIC STRATEGIES, LLC

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 MIDDLE EAST FZE

    By: /s/ Rafael Lopez Espinosa
    Name: Rafael Lopez Espinosa
    Title: Authorized Person


    STEVEN A. COHEN

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    Get the next $AFMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AFMD

    DatePrice TargetRatingAnalyst
    5/14/2025Buy → Neutral
    H.C. Wainwright
    5/13/2025Outperform → Market Perform
    Leerink Partners
    12/12/2022$6.00Buy
    H.C. Wainwright
    10/10/2022$9.00 → $2.00Buy → Hold
    Stifel
    8/18/2022Overweight
    Wells Fargo
    3/31/2022$7.00Overweight
    Piper Sandler
    2/23/2022$12.00Overweight
    Cantor Fitzgerald
    10/21/2021$10.00Buy
    Truist
    More analyst ratings

    $AFMD
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Affimed N.V.

      SCHEDULE 13G/A - Affimed N.V. (0001608390) (Subject)

      5/20/25 4:01:22 PM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Affimed N.V.

      6-K - Affimed N.V. (0001608390) (Filer)

      5/14/25 7:16:40 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Affimed N.V.

      6-K - Affimed N.V. (0001608390) (Filer)

      5/13/25 8:22:43 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AFMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Affimed Announces Receipt of Nasdaq Delisting Notice

      MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the "Staff") notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company's common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist the Company's securities from The Nasdaq Stock Market ("Nasdaq")

      5/14/25 6:45:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Announces Filing for the Opening of Insolvency Proceedings

      MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the "Company") has been engaged in discussions with potential investors and partners with respect to potential strategic transactions to raise additional capital. Despite its continuous and ongoing fundraising efforts, the Company has not been able to raise sufficient additional funds to continue the operations of the Company and

      5/13/25 8:15:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

      An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher drug exposure (above median) leads to improved objective response rate (33.3% vs 5.6%) and longer progression free survival (PFS) (7.3 mo. vs 2.9 mo.) without a negative impact on safetyThese findings will be incorporated in future AFM24 trials to further improve efficacy outcomes of patients treated with AFM24 MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an ex

      4/29/25 10:00:00 AM ET
      $AFMD
      Biotechnology: Pharmaceutical Preparations
      Health Care